The first patient was dosed at the Memorial Sloan Kettering Cancer Center in US. Credit: Sam Moghadam Khamseh on Unsplash.

Avacta Group has dosed the first patient in the US in the dose-escalation portion of its Phase I trial of AVA6000 to treat patients with locally advanced and/or metastatic solid tumours that are known to be FAP-positive.

The patient was dosed at the Memorial Sloan Kettering Cancer Center in New York.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase I first-in-human (FIH), open-label, multicentre, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000 monotherapy given intravenously (IV) to the targeted patients.

It will be carried out in two parts, Phase Ia dose escalation and Phase Ib dose expansion.

During Phase Ia, the safety, tolerability and maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of AVA6000, administered as monotherapy will be examined.

See Also:

Phase Ib will include one to three expansion arms in specific tumour types to investigate the safety and tolerability of AVA6000 at the MTD or RP2D when given as monotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase I trial aims to enrol 80 subjects, with plan to complete it by 30 June 2023.

AVA6000 is a tumour targeted form of doxorubicin and represents Avacta’s first therapeutic product developed using its proprietary pre|CISION technology.

Avacta Group CEO Dr Alastair Smith said: “The US trial sites in New York and Seattle will play a key role, along with other sites in the UK and US, in this multi-centre trial both in the dose escalation phase and in the dose expansion phase which we expect to begin in the second half of the year.”